Showing 1245 results
-
Ad hoc release /Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission…
-
Press release /Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercializedNovartis to establish…
-
Press release /Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint[1] PALLADIUM is part of Phase III PLATINUM clinical development program,…
-
Press release /Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint[1],[2] IRIDIUM is largest study in Phase III PLATINUM clinical…
-
Ad hoc release /In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only…
-
Press release /New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate major milestone gainUpdated results from global…
-
Press release /Early combination treatment strategy with vildagliptin (Galvus®) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients[1],[2] The landmark VERIFY study is…
-
Ad hoc release /Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met [1] Novartis has…
-
Press release /Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS)[1]; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20…
-
Press release /Monitoring disease activity and treatment effectiveness in MS patients in real-time is a serious challenge for physicians New data show how the use of two central nervous system-derived…